LNA-antisense rivals siRNA for gene silencing

Jan Stenvang Jepsen; Jesper Wengel; Jan Stenvang

LNA-antisense rivals siRNA for gene silencing

Jan Stenvang Jepsen, Jesper Wengel, Jan Stenvang

92 Citations (Scopus)

Abstract

Locked nucleic acid (LNA) is a class of nucleic acid analogs possessing unprecedented binding affinity toward complementary DNA and RNA while obeying the Watson-Crick base-pairing rules. For efficient gene silencing in vitro and in vivo, fully modified or chimeric LNA oligonucleotides have been applied. LNA oligonucleotides are commercially available, can be transfected using standard techniques, are non-toxic, lead to increased target accessibility, can be designed to activate RNase H, and function in steric block approaches. LNA-Antisense, including gapmer LNA containing a central DNA or phosphorothioate-DNA segment flanked by LNA gaps, rivals siRNA as the technology of choice for target validation and therapeutic applications.

Original language	English
Journal	Current Opinion in Drug Discovery & Development
Volume	7
Issue number	2
Pages (from-to)	188-94
Number of pages	7
ISSN	1367-6733
Publication status	Published - Mar 2004

Keywords

Animals
Drug Design
Gene Silencing
Genetic Therapy
Humans
Oligonucleotides
Oligonucleotides, Antisense
RNA, Small Interfering
Ribonuclease H

Cite this

@article{051374d4f0524ddc96f45d09b11230ad,

title = "LNA-antisense rivals siRNA for gene silencing",

abstract = "Locked nucleic acid (LNA) is a class of nucleic acid analogs possessing unprecedented binding affinity toward complementary DNA and RNA while obeying the Watson-Crick base-pairing rules. For efficient gene silencing in vitro and in vivo, fully modified or chimeric LNA oligonucleotides have been applied. LNA oligonucleotides are commercially available, can be transfected using standard techniques, are non-toxic, lead to increased target accessibility, can be designed to activate RNase H, and function in steric block approaches. LNA-Antisense, including gapmer LNA containing a central DNA or phosphorothioate-DNA segment flanked by LNA gaps, rivals siRNA as the technology of choice for target validation and therapeutic applications.",

keywords = "Animals, Drug Design, Gene Silencing, Genetic Therapy, Humans, Oligonucleotides, Oligonucleotides, Antisense, RNA, Small Interfering, Ribonuclease H",

author = "Jepsen, {Jan Stenvang} and Jesper Wengel and Jan Stenvang",

year = "2004",

month = mar,

language = "English",

volume = "7",

pages = "188--94",

journal = "Current Opinion in Drug Discovery and Development",

issn = "1367-6733",

publisher = "Current Drugs Ltd",

number = "2",

}

TY - JOUR

T1 - LNA-antisense rivals siRNA for gene silencing

AU - Jepsen, Jan Stenvang

AU - Wengel, Jesper

AU - Stenvang, Jan

PY - 2004/3

Y1 - 2004/3

N2 - Locked nucleic acid (LNA) is a class of nucleic acid analogs possessing unprecedented binding affinity toward complementary DNA and RNA while obeying the Watson-Crick base-pairing rules. For efficient gene silencing in vitro and in vivo, fully modified or chimeric LNA oligonucleotides have been applied. LNA oligonucleotides are commercially available, can be transfected using standard techniques, are non-toxic, lead to increased target accessibility, can be designed to activate RNase H, and function in steric block approaches. LNA-Antisense, including gapmer LNA containing a central DNA or phosphorothioate-DNA segment flanked by LNA gaps, rivals siRNA as the technology of choice for target validation and therapeutic applications.

AB - Locked nucleic acid (LNA) is a class of nucleic acid analogs possessing unprecedented binding affinity toward complementary DNA and RNA while obeying the Watson-Crick base-pairing rules. For efficient gene silencing in vitro and in vivo, fully modified or chimeric LNA oligonucleotides have been applied. LNA oligonucleotides are commercially available, can be transfected using standard techniques, are non-toxic, lead to increased target accessibility, can be designed to activate RNase H, and function in steric block approaches. LNA-Antisense, including gapmer LNA containing a central DNA or phosphorothioate-DNA segment flanked by LNA gaps, rivals siRNA as the technology of choice for target validation and therapeutic applications.

KW - Animals

KW - Drug Design

KW - Gene Silencing

KW - Genetic Therapy

KW - Humans

KW - Oligonucleotides

KW - Oligonucleotides, Antisense

KW - RNA, Small Interfering

KW - Ribonuclease H

M3 - Journal article

C2 - 15603252

SN - 1367-6733

VL - 7

SP - 188

EP - 194

JO - Current Opinion in Drug Discovery and Development

JF - Current Opinion in Drug Discovery and Development

IS - 2

ER -

LNA-antisense rivals siRNA for gene silencing

Abstract

Keywords

Fingerprint

Cite this